III. Contraindications

IV. Mechanism

V. Dosing: Adults

  1. Hypertension
    1. Start 16 mg orally daily
      1. Start 8 mg daily with concurrent Diuretic, elderly or GFR 30 to 60 ml/min/1.73m2
    2. Maximum 32 mg/day
  2. Congestive Heart Failure
    1. Start 4 mg orally daily
    2. May double dose every 2 weeks as needed
    3. Maximum 32 mg/day

VI. Dosing: Children

  1. Hypertension
    1. Age 1 to 5 years
      1. Start 0.2 mg/kg oral suspension
      2. Target 0.05 to 0.4 mg/kg/day
    2. Age 6 to 16 years and weight <50 kg
      1. Start 4 to 8 mg/day
      2. Target 4 to 16 mg/day
    3. Age 6 to 16 years and weight >50 kg
      1. Start 8 to 16 mg/day
      2. Target 4 to 32 mg/day
    4. Maximum: 0.4 mg/kg/day up to 32 mg

VII. Adverse Effects

VIII. Safety

  1. See Angiotensin Receptor Blocker
  2. Pregnancy Category X
  3. Unknown Safety in Lactation

X. References

  1. (2018) Presc Lett, Resource #340901, Angiotensin Receptor Blocker (ARB) Antihypertensive Dose Comparison
  2. (2020) Med Lett Drugs Ther 62(1598): 73-80
  3. Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 66-7
  4. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

candesartan (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
CANDESARTAN CILEXETIL 16 MG TB Generic $0.79 each
CANDESARTAN CILEXETIL 32 MG TB Generic $0.96 each
CANDESARTAN CILEXETIL 4 MG TAB Generic $0.80 each
CANDESARTAN CILEXETIL 8 MG TAB Generic $0.77 each
CANDESARTAN-HYDROCHLOROTHIAZIDE 16-12.5 MG TB Generic $1.12 each
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB Generic $1.76 each
CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB Generic $1.47 each

Ontology: candesartan (C0717550)

Definition (NCI) A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. Candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C081643
SnomedCT 108587008, 372512008
LNC LP171390-0
English 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole, 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-benzoimidazole-4-carboxylic Acid, candesartan [Chemical/Ingredient], CANDESARTAN, candesartan, Candesartan (product), Candesartan (substance), Candesartan
Spanish candesartano (sustancia), candesartano, candesartán (producto), candesartán (sustancia), candesartán

Ontology: Atacand (C0718711)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C077793
English Atacand, atacand, blopress, Amias, Blopress, Astra brand of candesartan cilexetil, AstraZeneca brand of candesartan cilexetil, Kenzen, Promed brand of candesartan cilexetil, Takeda brand of candesartan cilexetil